

CITATION REPORT

List of articles citing

Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study

DOI: 10.1006/rtp.2002.1550

Regulatory Toxicology and Pharmacology, 2002, 35, 320-6.

Source: <https://exaly.com/paper-pdf/34073468/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
30	The bisphosphonate ibandronate stimulates reverse cholesterol transport out of monocytoïd cells by enhanced ABCA1 transcription. <i>Biochemical and Biophysical Research Communications</i> , 2003 , 307, 23-30 ⁴	3.4	10
29	Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. <i>Osteoporosis International</i> , 2005 , 16, 1989-98	5.3	17
28	Yearly zoledronic acid in postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , 2007 , 357, 711; author reply 714-5	59.2	10
27	Safety considerations with bisphosphonates for the treatment of osteoporosis. <i>Drug Safety</i> , 2007 , 30, 755-63	5.1	93
26	Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors. <i>Bone</i> , 2008 , 43, 279-283	4.7	20
25	Adverse-effect profiles of bisphosphonates are largely determined by their route of administration. <i>Drugs and Therapy Perspectives</i> , 2008 , 24, 23-26	1.5	
24	Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. <i>BMC Musculoskeletal Disorders</i> , 2009 , 10, 113	2.8	40
23	Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. <i>American Journal of the Medical Sciences</i> , 2010 , 339, 519-24	2.2	18
22	Potential mediators of the mortality reduction with zoledronic acid after hip fracture. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 91-7	6.3	112
21	Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. <i>Osteoporosis International</i> , 2013 , 24, 271-7	5.3	55
20	Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 984-91	6.3	41
19	Heart failure in patients treated with bisphosphonates. <i>Journal of Internal Medicine</i> , 2013 , 274, 342-50	10.8	18
18	Long-term risks of bisphosphonate therapy. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014 , 58, 523-9		16
17	Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1422-1434	6.3	43
16	Reduced Bone Loss Is Associated With Reduced Mortality Risk in Subjects Exposed to Nitrogen Bisphosphonates: A Mediation Analysis. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 2001-2011	6.3	13
15	Bisphosphonate use and incident cardiovascular events among older breast cancer survivors. <i>Breast</i> , 2019 , 47, 28-32	3.6	1
14	The Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population-Based Cohort Study. <i>Journal of the American Medical Directors Association</i> , 2020 , 21, 811-816	5.9	4

13	Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. <i>Drugs</i> , 2020 , 80, 1537-1552	12.1	16
12	Bisphosphonates and lifespan. <i>Bone</i> , 2020 , 141, 115566	4.7	13
11	Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: A population-based study. <i>Atherosclerosis</i> , 2020 , 301, 1-7	3.1	2
10	Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5779-88	5.6	23
9	Measurement of serum homocysteine is useful to achieve health promotion. <i>Health Evaluation and Promotion</i> , 2012 , 39, 602-605	0.1	
8	Clinical significance of serum homocysteine in the association between atherosclerosis and osteoporosis. <i>Health Evaluation and Promotion</i> , 2013 , 40, 383-389	0.1	
7	Antiresorptive Therapy, Mortality and Cancer Incidence. 2016 , 265-278		
6	Therapeutic perspectives. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2008 , 5, 45-8		2
5	Mortality and osteoporotic fractures: is the link causal, and is it modifiable?. <i>Clinical and Experimental Rheumatology</i> , 2008 , 26, S125-37	2.2	49
4	Response to Letter. "Romosozumab and cardiovascular safety- should we learn lessons from Pioglitazone?". <i>Osteoporosis International</i> , 2022 , 1	5.3	
3	Reduced all-cause mortality with bisphosphonates among post-fracture osteoporosis patients: a nationwide study and systematic review.. <i>Clinical Pharmacology and Therapeutics</i> , 2022 ,	6.1	0
2	Novel formulations of oral bisphosphonates in the treatment of osteoporosis.		0
1	Antiresorptive Medication Use Is not Associated With Acute Cardiovascular Risk: An Observational Study.		0